The addition of other monoclonal antibodies (mAbs), such as pertuzumab, to standard anti-HER2 therapy has led to an over 90% three-year invasive disease-free survival rate in HER2+ BC [156]. The gene discussed is ERBB2; the disease is breast cancer.